The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin Potency Testing
暂无分享,去创建一个
Andreas Luch | Barbara Grune | Horst Spielmann | Manfred Liebsch | Frank Gessler | Gerd Bicker | Dorothea Sesardic | D. Dressler | M. Stephens | A. Luch | I. Ruhdel | H. Spielmann | M. Vey | D. Sesardic | H. Bigalke | Sarah Adler | Dirk Dressler | M. Liebsch | S. Adler | B. Grune | F. Gessler | Hans Bigalke | Christopher Bishop | Jörg Blümel | Joan Fitzgerald | Heide Heuschen | Birgit Kegel | Catherine Milne | Andrew Pickett | Heidemarie Ratsch | Irmela Ruhdel | Martin Stephens | Gerhard Stiens | Peter D. Thornton | René Thürmer | Martin Vey | P. D. Thornton | C. Milne | G. Stiens | A. Pickett | J. Blümel | B. Kegel | R. Thürmer | Gerd Bicker | Joan M. Fitzgerald | Christopher Bishop | Heide Heuschen | H. Ratsch
[1] K. Krampfl,et al. Synaptic currents and transmitter responses in human NT2 neurons differentiated in aggregate culture , 2010, Neuroscience Letters.
[2] M. Stern,et al. Cellular phenotypes of human model neurons (NT2) after differentiation in aggregate culture , 2009, Cell and Tissue Research.
[3] Anika Ashok,et al. ICH Harmonised Tripartite Guideline , 2009 .
[4] D. Sesardic,et al. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. , 2009, Toxicon : official journal of the International Society on Toxinology.
[5] S. Dodd,et al. The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations. , 2008, Toxicon : official journal of the International Society on Toxinology.
[6] K. Shakesheff,et al. The Intercostal NMJ Assay — A New Alternative to the Conventional LD50 Assay for the Determination of the Therapeutic Potency of Botulinum Toxin Preparations , 2008, Alternatives to laboratory animals : ATLA.
[7] Eric A. Johnson,et al. A neuronal cell‐based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies , 2007, FEBS letters.
[8] François Paquet-Durand,et al. Human model neurons in studies of brain cell damage and neural repair. , 2007, Current molecular medicine.
[9] Dorothea Sesardic,et al. Detection of antibodies against botulinum toxins , 2004, Movement disorders : official journal of the Movement Disorder Society.
[10] D. Sesardic,et al. Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. , 2003, Biologicals : journal of the International Association of Biological Standardization.
[11] K. Aoki,et al. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. , 2001, Toxicon : official journal of the International Society on Toxinology.
[12] Raymond C. Stevens,et al. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Å resolution , 2000, Nature Structural Biology.
[13] G. Schiavo,et al. Neurotoxins affecting neuroexocytosis. , 2000, Physiological reviews.
[14] R. Stevens,et al. Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. , 1997, Protein expression and purification.
[15] D Sesardic,et al. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. , 1997, Microbiology.
[16] K. Wohlfarth,et al. Botulinum A toxins: units versus units , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[17] D. Sesardic,et al. Therapeutic botulinum type A toxin: factors affecting potency. , 1996, Toxicon : official journal of the International Society on Toxinology.
[18] R. G. Das,et al. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. , 1996, Pharmacology & toxicology.
[19] G. Schiavo,et al. Botulinum neurotoxins are zinc proteins. , 1992, The Journal of biological chemistry.
[20] J. Black,et al. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis , 1986, The Journal of cell biology.
[21] J. Black,et al. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization , 1984, Nature.
[22] L. Simpson. The origin, structure, and pharmacological activity of botulinum toxin. , 1981, Pharmacological reviews.
[23] Wang Yin-chun. Biological characteristics and quality of botulinum toxin type A for injection , 2012 .
[24] Kurt W Simons. Open letter to the German Chancellor Dr. Angela Merkel. Council Directive on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. , 2010, ALTEX.
[25] J. Abraham. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .
[26] D. Sesardic,et al. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. , 2008, Journal of immunological methods.
[27] K. Roger Aoki. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. , 2002, Toxicon : official journal of the International Society on Toxinology.
[28] TG 442D. OECD GUIDELINE FOR THE TESTING OF CHEMICALS In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method , 2000 .
[29] R E Gaines Das,et al. Validation of in vitro assays for botulinum toxin: a case study. , 1999, Developments in biological standardization.
[30] F. Brown,et al. Quality of biotechnological products : Stability testing of biotechnological/ biological products : International Conference on Harmonisation (ICH) , 1998 .
[31] L. Simpson. Molecular pharmacology of botulinum toxin and tetanus toxin. , 1986, Annual review of pharmacology and toxicology.
[32] T. H. Allegri. The Code of Federal Regulations , 1986 .
[33] L. Simpson. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. , 1980, The Journal of pharmacology and experimental therapeutics.